Hereditary antithrombin deficiency (antithrombin III deficiency / thrombophilia type 7) OMIM 613118

In Hereditary antithrombin deficiency (SERPINC1, OMIM 613118), the master switch sits on the ↑ UP branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4704, γ 1.3717, spinodal 0.6184). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Hereditary antithrombin deficiency is an R19 double-well emerged from the real proximal-promoter DNA of SERPINC1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↑ UP [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.3717
barrier
0.4704
spinodal
0.6184
s_on / s_off
1.1712 / -1.1712
fragility
0.59
corrective polarity
clear
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4704 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: decreasegeometric rank 0.59
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating F2 does NOT relieve the disease branch in a SERPINC1 model, the h-restore(clear) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual SERPINC1 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: antithrombin concentrate (plasma-derived / recombinant antithrombin); direct factor Xa inhibitor (e.g. rivaroxaban / apixaban); vitamin-K antagonist (warfarin). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
antithrombin concentrate (plasma-derived / recombinant antithrombin)
Recombinant antithrombin (ATryn) FDA 2009 / plasma-derived antithrombin (Thrombate III); peri-operative/peripartum use in hereditary antithrombin deficiency
decreaseapproved4✓ in use
direct factor Xa inhibitor (e.g. rivaroxaban / apixaban)
EINSTEIN/AMPLIFY DOAC programmes (factor Xa inhibition in venous thromboembolism); antithrombin-independent mechanism
decreaseapproved4✓ in use
vitamin-K antagonist (warfarin)
Long-standing anticoagulation for inherited thrombophilia / recurrent VTE
decreaseapproved4✓ in use
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

antithrombin (human / recombinant alfa)✓ recovered standarddir: decrease · approved
Class. antithrombin replacement (plasma-derived or recombinant)
Mechanism. Infused antithrombin (plasma-purified or recombinant alfa) replaces the deficient SERPINC1 product, restoring the serpin brake on thrombin and factor Xa and thereby lowering the procoagulant drive the inherited deficiency leaves unchecked. Direction on the disease axis: decrease / oppose the excess thrombotic drive -- achieved by restoring the missing inhibitor (the same replacement-as-clear framing the corpus uses elsewhere). Engaged node: SERPINC1 -- the agent is the gene's product. Allele scope: agnostic -- supplies functional inhibitor regardless of the SERPINC1 variant. Gene-specific to SERPINC1, so it does not spill to other thrombophilia genes (e.g. F5); used for high-risk windows (peri-operative / peri-partum) where the inherited brake is most needed. The direction recovers an approved indication.
✓ This is a rediscovery. Antithrombin replacement (Thrombate III / ATryn) is approved for hereditary antithrombin deficiency to prevent peri-operative / peri-partum thromboembolism; restoring the missing SERPINC1 brake to lower the thrombotic drive is the disease-axis decrease direction, recovering an approved indication. Gene-scoped to SERPINC1 (no spill to F5).
Safety (qualitative; no magnitude). replacement biologic; bleeding risk when combined with anticoagulants, plus infusion/hypersensitivity signals on label (qualitative; no magnitude); used for defined high-risk windows
Falsifier. If antithrombin (human / recombinant alfa) (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the UP [F] disease branch in a SERPINC1 model, the h-restore(clear) direction is refuted for antithrombin (human / recombinant alfa) here.
Source: FDA label: antithrombin III (human) (Thrombate III) / antithrombin alfa (ATryn), hereditary antithrombin deficiency
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of SERPINC1; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).